Effect of Different Frequencies of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With ESLD
Key facts
- Who runs it
- General Hospital of Shenyang Military Region
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 92 people enrolled
- Started
- 5 Mar 2024
- Ended
- 30 Dec 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- umbilical cord-mesenchymal stem cells
- Record updated
- 31 March 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- 1. 18-80 years old
- 2. End-stage liver disease
- 3. Signed informed consent
Who cannot take part
- 2. Liver transplantation recipients
- 6. Interferon or glucocorticoid therapy within 1 year
- 3. Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases
- 4. Other diseases that may seriously affect the survival
- 5. Human immunodeficiency syndrome
- 7. Treated for mental illness
- 10. Allergic asthma, allergic urticaria, eczema, or a history of multiple drug and food allergies
- 1. Tumours of the liver or other organs
- 8. Participation in other clinical trials within 30 days
- 9. Pregnant or breastfeeding subjects
- 11. Other circumstances that are unsuitable for participation in this study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues. Multiple studies have shown that mesenchymal stem cell has good safety and effectiveness in improving acute or chronic liver injury. Randomized controlled trials have confirmed the efficacy of single infusion of stem cells in treating ESLD. It seems that the multiple infusion is better than single infusion.
The 2 groups in the trial
- Single-infusion groupTreatment being tested
Single peripheral venous infusion of stem cells
Treatment: umbilical cord-mesenchymal stem cells
- Double-infusion groupTreatment being tested
Repeated peripheral venous infusion of stem cells within one month
Treatment: umbilical cord-mesenchymal stem cells
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Different Frequencies of Human Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With End-stage Liver Disease
- Record updated
- 31 March 2026